Med Life SA · BVB:M
Med Life SA — H1 2021 Earnings Presentation
18 slides from Med Life SA's earnings presentation, Aug 27, 2021
Slide 1: H1 2021 Financial Results
H1 2021 Financial Results Conference call presentation 27 August, 2021
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 • Snapshot Highlights 6m 2021 • Key messages 6m 2021 • Outlook AGENDA Financial overview • Consolidated Statement of Profit and Loss 2 • • Consolidated Statement of Financial Position Consolidated Statement of Cash Flow Q&A Session 3 3/
Slide 4: Highlights 6m 2021
Highlights 6m 2021 • Snapshot • Key messages 6m 2021 • Outlook 1 4/
Slide 5: Snapshot
Snapshot ➢ Pro-forma Sales of RON 741m RON in 6m 2021, increase by 57.8% compared to 6m 2020; ➢ IFRS Sales for 6m 2021 of 677.3m RON, increased by 44.2% compared to 6m 2020 (42.4% like to like increase); ➢ Strong operating performance, in line with the strategy of recent years: -- 21.2% Pro-forma EB
Slide 6: Key messages 6m 2021
Key messages 6m 2021 ➢ Clinics: focused on the development of new products in outpatient units, from pre & post covid screening packages to prevention packages for patients with chronic pathology. Revenue increased by 36.6% vs. 6m 2020, with 29.6% increase in traffic and 5.4% increase in average fee
Slide 7: Key messages 6m 2021 (Cont.)
Key messages 6m 2021 (Cont.) ➢ Corporate: developed dedicated programs for the corporate segment, as employers become more and more concerned about the health of their employees; 10.4% increase in revenue, with a portfolio of subscriptions higher by 8% as compared to 6m 2020 (730k HPP). ➢ Pharmacies
Slide 8: Operational KPIs – supporting annex for BL evolution
Operational KPIs – supporting annex for BL evolution 8/ 1. Highlights 2021 2. Financial overview 3. Q&A Session
Slide 9: Key messages 6m 2021 (Cont.)
Key messages 6m 2021 (Cont.) ➢ First 6 months of 2021 marked the increase of existing facilities by 40 million euros by signing a syndicated loan in total amount of approximately 143 million euros + additional 50 million euros submitted to approval to shareholders: a total of 90 million euros funds
Slide 10: Outlook
Outlook Main development segments include: 1. M&A and digitization programs will be a priority in the strategy plan; We have completed the acquisition of CED Pharma and Pharmachem Distribution and we are in advanced discussions for other acquisitions. We believe that by the end of this year we will
Slide 11: Financial overview
Financial overview Consolidated Stetement of Profit and Loss Consolidated Statement of Financial Position Consolidated Stetement of Cash Flow 2 11 /
Slide 12: Consolidated Statement of Profit and Loss (1/3)
Consolidated Statement of Profit and Loss (1/3) 12 / 1.Highlights 2021 2. Financial overview 3. Q&A Session
Slide 13: Consolidated Statement of Profit and Loss (2/3)
Consolidated Statement of Profit and Loss (2/3) explained 1) 6m 2021 Pro-forma vs. 6m 2020 IFRS ❑ Sales increased by 57.8%, to 741m RON ❑ OPEX increased by 45.5%, to 640.7m RON ❑ More than threefold increase in EBIT, to 103.8m RON, leading to 14.0% margin (6.6% in the same period last year), due to
Slide 14: Consolidated Statement of Profit and Loss (3/3)
Consolidated Statement of Profit and Loss (3/3) OPEX Evolution Release of 5.9 p.p. in EBITDA margin due to: ➢ Increase in Consumable & repair materials with 1.9 p.p. of Sales due to reagents and materials related to PCR testing; ➢ Decrease in Commodities with 1.2 p.p. of Sales: decrease of Pharmacie
Slide 15: Consolidated Statement of Financial Position (1/2)
Consolidated Statement of Financial Position (1/2) 15 / 1.Highlights 2021 2. Financial overview 3. Q&A Session
Slide 16: Consolidated Statement of Financial Position (2/2)
Consolidated Statement of Financial Position (2/2) Debt position 16 / 1.Highlights 2021 2. Financial overview 3. Q&A Session
Slide 17: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow Cash flow for the period characterized by good operating performance: 1. two folded increase in net cash from operating activities; 2. 156% increase in cash used in investing activities; 3. Cash used in financing activities of 8m RON 17 / 1.Highlights 2021 2. Fina
Slide 18: Q&A Session Thank you!
Q&A Session Thank you! 3 18 /